Dr. Wenquan Zou has been working on the pathogenesis and diagnosis of prion diseases and other neurodegenerative diseases including Parkinson’s disease (PD) and Alzheimer’s disease. The Zou lab is a pioneer in developing skin biomarkers using ultrasensitive technologies including RT-QuIC and PMCA assays for postmortem and premortem diagnosis of prion diseases, PD, and Alzheimer’s disease. These efforts have been supported by the National Institutes of Health (NIH), The Michael J. Fox Foundation, Alzheimer’s Association, Alzheimer’s Research UK, Weston Brain Institute   and CJD Foundation. Some of these studies have been published in highly prestigious journals, such as Science Translational Medicine (2017), Nature Communications (2019), JAMA Neurology (2020), Neurology (2021) and Acta Neuropathologica Communications (2021). Dr. Zou is an ad hoc reviewer for   NIH, the Department of Defense and Alzheimer’s Association and for journals including the New England Journal of Medicine, Acta Neuropathologica, PLoS Pathogen and the Annals of Neurology.